The strikingly different tumour phenotypes in patients with SMARCB1-related SWN as compared to patients with RTPS1 indicate that the types and consequences of germline pathogenic SMARCB1 variants must be different between these patient groups and will affect different tumour precursor cells. This evidence concerns the gene SMARCB1 and neoplasm.